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Objective: An oral lipid based formulation that exhibits tropical stability (iCo-010) was developed to enhance the
absorption of orally administered amphotericin B (AmB). iCo-010 has previously shown high efficacy in an acute
model of systemic candidiasis in rats, directing the focus of this study to be its efficacy in a chronic model of
systemic candidiasis in mice.
Methods: Mice were infected with 0.6 to 1×108 CFUs of Candida albicans ATCC 18804 strain by tail vein injection
and were left for three days to develop the infection after which time treatment was initiated. The infected animals
were assigned to the following treatment groups: no treatment (control) or iCo-010 at 5, 10 and 20 mg/kg
administered by oral gavage once daily (QD) for 5 consecutive days. The animals were sacrificed 7 days after the
last dose and the concentration of AmB and the fungal burden were assessed within the liver, kidneys, heart, lungs,
spleen and brain.
Results: Although the infection was relatively low (~ 60–100 CFUs/ 1 ml tissue homogenate) in the liver, lungs and
heart, the infection level was very high (70 000 CFUs / 1 ml tissue homogenate) in the kidney tissues for the control
group. The highest concentrations of AmB were recovered in the kidneys and the spleen. The fungal burden in the
tissues was lowered by 69-96% in the treatment groups when compared to the control group.
Conclusion: Oral iCo-010 is an effective treatment of systemic candidiasis in the mouse model.
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Amphotericin B (AmB) is a polyene macrolide antibiotic
used in the treatment of blood-borne fungal infections
(systemic candidiasis) and parasitic infections (visceral
leishmaniasis). However, its use is hampered by dose-
dependent nephrotoxicity and other acute side effects
associated with its intravenous administration [1]. In
addition, the high cost of the intravenous products and
the associated cost of patient hospitalization inhibit the
provision of affordable treatment in poor endemic areas
located in hot climate zones. Due to these clinical and* Correspondence: Kishor.Wasan@ubc.ca
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stated.financial implications the development of an oral AmB
formulation is an important endeavor aiming to substi-
tute the present intravenous products [2].
Scientists investigated a wide scope of oral AmB for-
mulations including carbon nanotubes [3,4], cochleate
[5-7] and lipid based formulations [8-11]. The carbon
nanotubes were tested in a visceral leishmaniasis model
in Syrian hamsters and showed high efficacy, however
the safety of carbon nanotubes in humans is still ques-
tionable [3]. The cochleate formulation was tested in a
systemic candidiasis model in mice, but it took 15 days
of treatment to lower the infection in the organs [12].
The lipid based formulations of AmB enhanced its
solubility and absorption, and reduced its nephrotoxi-
city [8-11]. However, only one lipid-based formulationl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication












































































































































































































































































































































Figure 1 Inoculation of Candida albicans and treatment protocol of iCo-010 in mice. (A) Inoculation of Candida albicans and treatment
protocol of iCo-010 in mice, (B) Comparison of the efficacy of oral AmB at 5, 10 and 20 mg/kg in the lipid-based iCo-010 formulation in the liver, lung,
heart, brain spleen and kidney tissues of a mouse model of invasive candidiasis. Animals were infected and allowed to establish the infection over two
days. The animals were treated for the next five consecutive days once daily and sacrificed 7 days following the completion of the treatment. Organs
were harvested and homogenized to count CFU of the fungus/1ml of tissue homogenate (Mean CFU count ±SEM). *p<0.05 significantly different
from the untreated control group. The purple column represents the control group, green column represents 5 mg/kg group, red column represent
10 mg/kg group and blue column represents 20 mg/kg group.
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Table 1 Concentration of AmB (ng/g, Mean +/− SEM) in
mouse tissues infected with Candida albicans 7 days after
the completion of 5 days oral iCo-010 treatment once
daily at 5, 10 and 20 mg/kg doses, (ND; non detectable)
Organ AmB concentration (ng/g tissue)
5 mg/kg (n=15) 10 mg/kg (n=13) 20 mg/kg (n=5)
Kidney




114.5 ± 26.7 202.5 ± 15.6 266.5 ± 29*
Lung
ND 46.2 ± 1.4 78.2 ± 7.5
Heart
ND 45 ± 11.6 121.4 ± 50.7
Brain
ND ND ND
*p<0.05 significantly different from the 5 mg/kg treatment group.
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tropical conditions [10]. The disposition profile of iCo-010
indicates the accumulation of AmB in the tissues after
multiple dosing allowing for therapeutic concentrations to
be reached [13,14]. In addition, iCo-010 showed dose
dependent efficacy in a rat model of acute systemic can-
didiasis after only 2 days of treatment [8]. Since rats have
no gall bladder and the way they process lipids is different
than man [15], studying the efficacy of iCo-010 in mice
which have a gall bladder is worth investigation, especially
since lipid digestion is a prerequisite for AmB absorption
from iCo-010. The objective of this study was to assess
the efficacy of iCo-010 formulation in a mouse model of
chronic systemic candidiasis infection.
Materials
Amphotericin B powder, D-alpha-tocopherol polyethylene
glycol succinate (TPGS) and 1-amino-4-nitronaphthalene
were purchased from Sigma-Aldrich (St Louis, MO, USA).
Peceol® (Glycerol monooleates) and Gelucire 44/14®
(Lauroyl polyoxylglycerides) were a gift from Gattefossé
Canada (Mississauga, Ontario, Canada).
Experimental methods
Preparation of Oral Amphotericin B (iCo-010) formulation
The preparation of iCo-010 was previously described
[10,16]. Briefly, AmB, suspended in ethanol, was mixed
with Peceol and Gelucire 44/14. VitE-TPGS (5% v/v)
was added to obtain a final AmB concentration of 5mg/ml.
The mixture was stirred for 1 hour with gentle warming
and ethanol was subsequently removed by use of a rotary
evaporator.
Animal study protocol
All animal study protocols were approved by The Uni-
versity of British Columbia’s Animal Care Committee.
Balb C mice (25–30 g body weight) were purchased
from Charles River Laboratories (Wilmington, MA) and
were kept at controlled temperature and humidity with
12 h light: dark cycles. Each animal was infected with
0.6 to 1×108 CFUs of Candida albicans ATCC 18804
strain by tail vein injection. The animals were left for
three days to develop the infection after which the treat-
ment was started. The infected animals were assigned to
the following groups: no treatment (control) or iCo-010
at 5, 10 and 20 mg/kg administered by oral gavage once
daily (QD) for 5 consecutive days with free access to
food and water. After the 5 days of treatment, the ani-
mals were left for 7 days to recover and then sacrificed
(Figure 1A). The right kidney, spleen, liver, heart, brain
and lungs were harvested and immediately weighed. The
organs were homogenized following the addition of
sterile saline solution in a ratio of 1:2 (tissue: saline).
An aliquot of the organ homogenate was immediatelyprocessed for plating and counting of colony forming
units (CFUs) [8].
High performance liquid chromatography (HPLC) analysis
of Amphotericin B
AmB concentrations within tissue samples were deter-
mined using a previously developed and published HPLC
methods from our laboratory and others [9]. Briefly, 200
μL of tissue homogenate was spiked with 10 μL of internal
standard. A double volume of methanol was used to pre-
cipitate plasma proteins and to extract AmB into the
supernatant after centrifugation at 10000 rpm for 7 min at
15°C. A volume of 90 μL of the supernatant was injected
into the HPLC. The analysis was conducted on a BDS
Hypersil C18 column (5 μm, 250 × 4.6 mm, Thermo
Scientific, Waltham, MA). The lowest limit of quanti-
fication was 20 ng/gm.
Statistical analysis
The difference among the groups was assessed using
ANOVA test followed by Tukey’s post-hoc analysis for
more than two groups and considering p values of less
than 0.05 a significant difference. The percentage of re-
duction of the fungal burden was calculated using the
following formula:
The percentage of fungal burden reduction
¼ CFUsCont‐ CFUsTreatð Þ 100=CFUsCont
where CFUs is the colony forming units of the fungus
per 1 ml of tissue homogenate for the control group
(CFUs Cont) and the treated groups (CFUs Treat).
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While the infection was relatively low (~ 60–100 CFUs/
1 ml tissue homogenate) in the liver, lungs and heart,
the infection was very high (70 000 CFUs/1 ml tissue
homogenate) in the kidney tissues in the control group
(Figure 1B). Administration of iCo-010 significantly re-
duced the CFUs in all the organs as compared to the
control. There was no significant difference in the reduc-
tion of CFUs in the same organ among the iCo-010
treatment groups. In addition, there was a clear trend of
dose response in the kidneys and the spleen. The con-
centration of AmB in the tissues of the brain and liver
were below the limit of quantification of the HPLC
assay, in contrast; the highest concentrations of AmB were
recovered from the kidneys and the spleen (Table 1).
The efficacy of iCo-010 in the mouse model of sys-
temic candidiasis is worth investigation since mice pos-
sess a gall bladder, which is absent in rats used as the
animal model in the previous study [8]. The release of
bile secretion from the gall bladder plays an important
role in the emulsification and digestion of lipids, the
main constituent of iCo-010 [10].
The disease models in the previous and the present
study are different. In the present study, the remaining
infection was allowed to regrow for 7 days after stopping
the treatment allowing for a better estimation of the
remaining infection in the tissues. In our preliminary
studies, a period of 15 days was chosen as the humane
end point as the animals in the control group did not
survive or were sacrificed due to severe weight loss after
15 days post inoculation of the fungus. The level of the
infection in the organs was significantly reduced in com-
parison to the control group, which correlates to the ad-
ministrated doses of iCo-010, most significantly in the
spleen and kidney. It is worth noting that the high infec-
tion in the kidneys was reduced by 92% even after allo-
wing the infection to regrow for 7 days. This indicates
high efficacy of the formulation and high potential for
the complete eradication of the infection (Figure 1B).
The remaining concentrations of AmB in the tissues
declined throughout the 7 days after the treatment was
stopped and were below the quantification limits of the
HPLC assay in the liver and the brain. However, the
levels in the other tissues were high enough to be quan-
tified (except at the 5 mg/kg dose in the lungs), with the
highest recovery of AmB coming from the spleen and
the kidneys (Table 1). AmB is known to have high affi-
nity to renal tissues which was previously explained by
the high affinity of AmB to plasma LDL, which has high
receptor expression in renal tissues [17]. Nonetheless, it
is not clear why AmB was highly distributed to the
spleen tissues. It is worth noting that the infection in the
kidneys and the spleen was the highest among the or-
gans and at the same time both organs had the highestlevels of AmB. It is unclear if there is a correlation bet-
ween the level of infection and the level of AmB in the
tissues, where the recruitment of macrophages could
play a role in transferring the associated AmB to the in-
fected areas [18,19]. The suppression of infection was
significant in all the organs at all dose levels of iCo-010.
Conclusions
The 5 day treatment of iCo-010 significantly reduced the
fungal burden in the mouse organs even at the low dose
of 5 mg/kg. The re-grown colonies from 7 days post
treatment were 69-96% lower than the control group in-
dicating that the single daily dose of iCo-010 for 5 days
is an effective treatment for systemic candidiasis.
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